Amarin Corp ADR (AMRN) stock forecast: Can it reach its 52-week high of $1.49

A share price of Amarin Corp ADR [AMRN] is currently trading at $1.05, down -0.94%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AMRN shares have gain 17.87% over the last week, with a monthly amount glided 10.62%, and seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

On 6, April 2024, New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups. In a post published today on Yahoo Finance, — Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels –.

From an analyst’s perspective:

Previously, Jefferies downgraded its rating to Hold on October 25, 2023, and dropped its price target to $1. On January 06, 2023, upgrade upgraded it’s rating to Buy and revised its price target to $3 on the stock. JP Morgan downgraded its rating to a Underweight. SVB Leerink downgraded its rating to a Mkt Perform and reduced its price target to $3 on May 05, 2022. H.C. Wainwright downgraded its rating to Neutral for this stock on May 05, 2022, and downed its price target to $3. In a note dated May 04, 2022, Northland Capital downgraded an Market Perform rating on this stock.

Amarin Corp ADR experienced fluctuations in its stock price throughout the past year between $0.65 and $1.49. Currently, Wall Street analysts expect the stock to reach $2.17 within the next 12 months. Amarin Corp ADR [NASDAQ: AMRN] shares were valued at $1.05 at the most recent close of the market. An investor can expect a potential return of 106.67% based on the average AMRN price forecast.

Analyzing the AMRN fundamentals

Trailing Twelve Months sales for Amarin Corp ADR [NASDAQ:AMRN] were 308.22M which represents -17.11% decline. Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.17%, and Net Profit Margin reading is -0.19%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.1 and Total Capital is -0.12. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.0200 points at the first support level, and at 0.9900 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.0700, and for the 2nd resistance point, it is at 1.0900.

Amarin Corp ADR [AMRN] reported earnings per share of -$0.01 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.03/share, meaning a difference of $0.02 and a surprise factor of 66.70%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.05 per share as compared to estimates of -$0.04 per share, a difference of -$0.01 representing a surprise of -25.00%.

Ratios To Look Out For

To put it in perspective, the Current Ratio for Amarin Corp ADR [NASDAQ:AMRN] is 2.80. Also, the Quick Ratio is 1.80, while the Cash Ratio stands at 0.77. Considering the valuation of this stock, the price to sales ratio is 1.39, the price to book ratio is 0.78.

Transactions by insiders

Recent insider trading involved Holt Patrick, President and CEO, that happened on Jan 22 ’24 when 14426.0 shares were purchased. Chief Scientific Officer, Ketchum Steven B completed a deal on Dec 12 ’23 to sell 34131.0 shares. Meanwhile, President and CEO Holt Patrick bought 0.3 million shares on Aug 16 ’23.

Related Posts